They are now in full commercialisation mode and the US has been deemed the most likely market for expansion of customer base.
The listing in the US is a double edged strategy. Firstly there is the access to investment which we all know is better in the US and secondly the listing makes Life Theraphutics more visible to suppliers and customers.
The recent options issue and subsequent underwriting by USB has satisfied the immediate working capital needs and positive cash flow from US activities should be sufficient to carry the working capital requirment going forward.
A deal with a UK distributor where the UK company will do the initial marketing and logistic work means that management can concentrate on the US in the knowledge that Europe is also being explored for further market growth.
All up the way I see it is that if their technology is as good as they say it is they are well positioned to take advantage of whatever comes their way.
